ClinicalTrials.gg
CompletedNCT06781957Updated Jan 26, 2026

Pharmacokinetics of FSH and hCG After a Single Subcutaneous Injection of Gonadotropins-IBSA

A Phase 1 interventional study of Gonadotropins Subcutaneos in OVARIAN STIMULATION and Infertility, sponsored by IBSA Institut Biochimique SA. Completed at 1 site in Canada. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by IBSA Institut Biochimique SA · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Infertility by IBSA Institut Biochimique SA — none open to participants now, none under way, none of them phase 3. Infertility · IBSA Institut Biochimique SA.

Enrollment
11th of 13
29 · median 152
Started
2024
with 1 other
Phase 1
3 of 13
none open now
Registered
13th of 13
by date

Among the 13 studies in Infertility by IBSA Institut Biochimique SA, this one is the 11th largest by enrollment, is one of 2 that started in 2024, is one of 3 in phase 1, and was the 13th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

None of the 13 studies in Infertility by IBSA Institut Biochimique SA is open now. The open studies under Infertility, anywhere →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Infertility by IBSA Institut Biochimique SA as a file.
02

Study summary

The objectives of this study is to evaluate the PK and the dose-proportionality of FSH and HCG following a single dose of Gonadotropins-IBSA, administered subcutaneously.

03

Conditions studied

  • OVARIAN STIMULATION
  • Infertility

Browse trials for

Keywords

  • gonadotropin
  • FSH
  • hCG
  • infertility
  • Controlled ovarian stimulation
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female of , non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), ≥18 and ≤45 years of age, with >18.5 and \<32.0 kg/m2 and body weight ≥45.0 kg.
  2. Healthy as defined by:

    1. the absence of illness and surgery within 4 weeks prior to dosing.
    2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
  3. Use of a COC containing at least 20 µg of ethinyl estradiol for at least 3 months prior to screening and willing to keep using the same oral until the end of the study. The usual regimen (with hormone-free interval or continuous dosing) will be allowed until Day -1. Subjects must agree to take the COC in a continuous manner (no hormone-free interval) from Day 1 to Day 72.
  4. Females who are sexually active with a non-sterile male partner (sterile male partners are defined as men vasectomized for atleast 3 months prior to dosing) must be willing to use a male condom with intravaginally applied spermicide or total abstinence from heterosexual intercourse (when this is in line with the preferred and usual lifestyle of the subject) from screening and throughout the study and for 30 days after the last study drug administration.
  5. Able to understand the study procedures and provide signed to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Any abnormal finding at physical examination at screening.
  2. Clinically significant abnormal laboratory test results or positive serology test results for surface antigen (HBsAg), virus (HCV) antibody, or (HIV) antigen and antibody at screening.
  3. Positive pregnancy test or lactating subject.
  4. Positive urine drug screen, urine cotinine test, or alcohol breath test.
  5. Known allergic reactions to FSH, hCG, other gonadotropins, or other related drugs, or to any in the formulation.
  6. Clinically significant abnormalities or vital signs abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.
  7. History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.
  8. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
  9. \<125 g/L, or hematocrit \<0.32 L/L at screening.
  10. FSH levels > 4 IU/L at admission in each period.
  11. Clinically significant history of an abnormal menstrual cycle
  12. Abnormal Pap smear prior to administration of the study drug (result is valid for 12 months).
  13. History of ovarian cysts or enlargement.
  14. History or presence of polycystic ovary syndrome.
  15. Presence of undiagnosed vaginal and/or urinary tract bleeding.
  16. History or presence of sex hormone dependent tumors of reproductive tract and accessory organs.
  17. History of hypothalamus or pituitary gland tumors.
  18. Personal history or strong family history (first degree relative) of coagulation disorders such as thromboembolic diseases (e.g., thrombophlebitis, pulmonary embolism or coagulation factors deficiency).
  19. History of rare hereditary galactose and/or lactose intolerance (e.g., congenital lactase deficiency [CLD] or glucose-galactose malabsorption [GGM]).
  20. Tattoos covering the potential study drug injection site or any skin conditions that would prevent the injection (e.g., psoriasis, major scar, etc.).
  21. Use of medications for the timeframes specified below, except for the subject's prescribed COC and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety (e.g., topical drug products without significant systemic absorption):

    1. depot injection or implant of any drug within 3 months prior to study drug administration.
    2. prescription medications within 14 days prior to study drug administration;
    3. any vaccine, including COVID-19 vaccine, within 14 days prior to study drug administration;
    4. over-the-counter (OTC) products and natural health products (including herbal remedies such as St. John's wort, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to study drug administration, with the exception of the occasional use of acetaminophen (up to 2 g daily);
  22. Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days prior to dosing, administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device administration.
  23. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing.
  24. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Gonadotropins 75 IU

    Single dose 75 IU

    Drug: Gonadotropins Subcutaneos

  • Experimental
    Gonadotropins 225 IU

    Single dose 225 IU

    Drug: Gonadotropins Subcutaneos

  • Experimental
    Gonadotropins 450 IU

    Single dose 450 IU

    Drug: Gonadotropins Subcutaneos

Interventions

  • DrugGonadotropins Subcutaneos

    Gonadotropins s.c. single dose

06

What researchers measure

Primary outcomes

  1. Primary PK endpoints FSH

    Day 72: AUC0-24

    Time frame: until 240 hours post dose

  2. Primary PK endpoints hCG

    Day 72: AUC0-24

    Time frame: until 240 hours post dose.

  3. Dose-proportionality of FSH

    AUC (using baseline-corrected data)

    Time frame: until 240 hours post dose

  4. Dose-proportionality of FSH

    Cmax (using baseline-corrected data)

    Time frame: until 240 hours post dose

  5. Dose-proportionality of hCG

    AUC (baseline correction)

    Time frame: until 240h post dose

  6. Dose-proportionality of hCG

    Cmax (baseline correction)

    Time frame: until 240h post dose

Secondary outcomes

  1. PD endpoints of Gonadotropins-IBSA

    Levels of inhibin B

    Time frame: until 240 hours post dose

  2. PD endpoints of Gonadotropins-IBSA

    Levels of estradiol (E2).

    Time frame: until 240 hours post dose

  3. Adverse events (AEs)

    Percentage of subjects with any AEs

    Time frame: From the signature of the Informed Consent until the end of the study

07

Study locations

1 site
  • Syneos Health
    Québec, Quebec GIP 0A2, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jan 2026, 15 months.

Of 28 phase 1 interventional studies under Infertility, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 38. This study's 15 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Jan 17, 2025
StartActual
Sep 15, 2024
Primary completionActual
Jan 13, 2026
CompletionActual
Jan 13, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06781957
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Sep 15, 2024
Primary completion
Jan 13, 2026
Completion
Jan 13, 2026
Last update
Jan 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion